{"result": "(\"entity\"<|>GLYCEMIC CONTROL<|>EVENT<|>Glycemic control refers to the management of blood glucose levels in individuals with diabetes, often involving the use of insulin and other medications.)\n##\n(\"entity\"<|>PHARMACOKINETIC PROFILES<|>EVENT<|>Pharmacokinetic profiles describe the absorption, distribution, metabolism, and excretion of drugs, including various types of insulin used in diabetes treatment.)\n##\n(\"entity\"<|>INSULINA LISPRO<|>EVENT<|>Insulina lispro is a rapid-acting insulin used to control blood sugar levels in diabetes patients, with a quick onset and short duration of action.)\n##\n(\"entity\"<|>INSULINA REGULAR<|>EVENT<|>Insulina regular is a short-acting insulin that helps manage blood glucose levels, typically administered before meals.)\n##\n(\"entity\"<|>INSULINA NPH<|>EVENT<|>Insulina NPH is an intermediate-acting insulin used in diabetes management, providing a longer duration of action compared to rapid-acting insulins.)\n##\n(\"entity\"<|>INSULINA GLARGINA<|>EVENT<|>Insulina glargina is a long-acting insulin that provides a steady release of insulin over 24 hours, used for basal insulin needs in diabetes management.)\n##\n(\"entity\"<|>INSULINA DETEMIR<|>EVENT<|>Insulina detemir is a long-acting insulin that offers a consistent level of insulin in the bloodstream, used for managing diabetes.)\n##\n(\"entity\"<|>INSULINA DEGLUDEC<|>EVENT<|>Insulina degludec is an ultra-long-acting insulin that provides flexibility in dosing and a prolonged duration of action for diabetes management.)\n##\n(\"relationship\"<|>GLYCEMIC CONTROL<|>INSULIN<|>Insulin is a key component in achieving glycemic control for individuals with diabetes, helping to lower blood glucose levels.<|>9)\n##\n(\"relationship\"<|>PHARMACOKINETIC PROFILES<|>INSULINA LISPRO<|>The pharmacokinetic profile of insulina lispro indicates its rapid absorption and short duration, making it suitable for postprandial glucose control.<|>8)\n##\n(\"relationship\"<|>PHARMACOKINETIC PROFILES<|>INSULINA REGULAR<|>The pharmacokinetic profile of insulina regular shows its onset and duration, which are important for meal-time management in diabetes.<|>8)\n##\n(\"relationship\"<|>PHARMACOKINETIC PROFILES<|>INSULINA NPH<|>The pharmacokinetic profile of insulina NPH provides insights into its intermediate action, which is useful for managing blood glucose levels throughout the day.<|>8)\n##\n(\"relationship\"<|>PHARMACOKINETIC PROFILES<|>INSULINA GLARGINA<|>The pharmacokinetic profile of insulina glargina demonstrates its long-acting properties, essential for maintaining stable blood glucose levels overnight.<|>8)\n##\n(\"relationship\"<|>PHARMACOKINETIC PROFILES<|>INSULINA DETEMIR<|>The pharmacokinetic profile of insulina detemir indicates its long duration of action, which is beneficial for basal insulin needs in diabetes management.<|>8)\n##\n(\"relationship\"<|>PHARMACOKINETIC PROFILES<|>INSULINA DEGLUDEC<|>The pharmacokinetic profile of insulina degludec shows its ultra-long-acting characteristics, allowing for flexible dosing in diabetes treatment.<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122:531-44.      COMENTARIO\n                                                                                                                                           Se debe utilizar un enfoque centrado en el paciente para guiar la elección de los agentes\n                                                                                                                                           farmacológicos. Las consideraciones incluyen                  comorbilidades (enfermedad             cardiovascu-\n                                                                                                                                           lar, insuficiencia cardíaca, enfermedad renal), riesgo de hipoglucemia, impacto en el peso,\n                                                                                                                                           coste, riesgo de efectos secundarios y preferencias del paciente.\n                                                                                                                                           Antes de iniciar una pauta avanzada que incluya insulina rápida,                       podría intensificarse la\n                                                                                                                                           pauta de tratamiento con opciones no insulínicas, si no estaban prescritas previamente\n\n\n\n122                                                                                                                                                                                                                                                                123\n---\n                                                                                                                                                                                                                                 DIABETES                          2\n\n\n\n         ni concurriera intolerancia y/o contraindicación, priorizando las terapias combinadas, con                                       administración subcutánea. En conjunto, estos cambios estructurales favorecen la disocia-\n         bajo riesgo de hipoglucemia, que favorezcan el control ponderal u otros factores de riesgo                                       ción de las moléculas de insulina, lo que se traduce en una absorción facilitada, más rápida,\n         cardiovascular. Si aun con estas medidas terapéuticas el sujeto presentara control glucé-                                        después de su administración en el tejido celular subcutáneo.\n         mico inadecuado, se valoraría añadir insulina rápida o cambiar la pauta previa a mezclas\n         bifásicas, en función de las características del paciente (evidencia E).                                                         Tabla 8. Perfil farmacocinético de las insulinas\n         Referencias:                                                                                                                                                                                   Inicio                 Pico            Duración eficaz\n         • American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.\n           Diabetes Care. 2019;42(Suppl 1):S90-102.                                                                                        Insulina lispro, aspart, glulisina                          5-15 min             45-75 min                 2-4 h\n                                                                                                                                           Insulina regular                                            ~30 min                 2-4 h                  5-8 h\n     66  Señale el perfil erróneo entre los siguientes perfiles farmacocinéticos de distintos                                              Insulina NPH                                                  ~2 h                 6-10 h                10-16 h\n         preparados de insulina:                                                                                                           Insulina detemir                                              ~2 h                Sin pico               12-20 h\n         A. Insulina glulisina. Inicio: 0,25 h. Pico: 1 h. Duración: 3-4 h.                                                                Insulina glargina                                             ~2 h                Sin pico               20-24 h\n         B. Insulina regular. Inicio: 1-3 h. Pico: 6-8 h. Duración: 12-16 h.                                                               Insulina glargina U-300                                       2-4 h               Sin pico               24-30 h\n         C. Insulina glargina U-300 Inicio: 1 h. Pico: 12-16 h. Duración: 32-34 h.                                                         Insulina degludec                                             2-4 h               Sin pico             Hasta 42 h\n         D.  Insulina detemir. Inicio: 1 h. Pico: 3-9 h. Duración: 6-24 h.                                                                Adaptado de: Manual SEEN de Endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de\n                                                                                                                                          2019).\n     67  En relación con la farmacocinética de las insulinas, señale la afirmación que no es\n         correcta:                                                                                                                        Los AIAR lispro, aspart y glulisina tienen propiedades farmacocinéticas y farmacodinámi-\n                                                                                                                                          cas bastante similares (tabla 8). En general, la inyección de los AIAR da lugar a una concen-\n         A. La absorción más rápida y la duración de acción más corta de los análogos rápidos de                                          tración máxima mayor y en la mitad de tiempo que la insulina regular humana (IRH). Los\n             insulina se basa en su mayor afinidad por el receptor de insulina y por las proteasas que                                    AIAR frente a la IRH reducen más eficazmente las excursiones glucémicas posprandiales\n             la degradan.                                                                                                                 (diferencia entre la glucemia preprandial y la glucemia posprandial de 1,5-2 h) y disminu-\n         B. La insulina no puede atravesar el endotelio para acceder a la circulación sanguínea                                           yen el riesgo de hipoglucemia tardía (antes de la siguiente ingesta). Además, la rapidez de\n             mientras no está en forma de dímero o de monómero.                                                                           acción de los AIAR permite una administr\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a professional organization that provides standards of medical care in diabetes and promotes research and education in diabetes management.)\n##\n(\"entity\"<|>DIABETES CARE<|>ORGANIZATION<|>Diabetes Care is a journal published by the American Diabetes Association that focuses on research and clinical practices related to diabetes treatment and management.)\n##\n(\"entity\"<|>INSULIN<|>EVENT<|>Insulin is a hormone used in the treatment of diabetes, with various types having different pharmacokinetic profiles.)\n##\n(\"entity\"<|>GLUCAGON-LIKE PEPTIDES<|>EVENT<|>Glucagon-like peptides are hormones that have therapeutic potential in the management of diabetes and related conditions.)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>DIABETES CARE<|>The American Diabetes Association publishes the journal Diabetes Care, which provides guidelines and research findings related to diabetes management.<|>8)\n##\n(\"relationship\"<|>INSULIN<|>GLUCAGON-LIKE PEPTIDES<|>Insulin and glucagon-like peptides are both involved in the pharmacological treatment of diabetes, with specific roles in glycemic control.<|>7)\n<|COMPLETE|>"}]}